BB Biotech's market cap is currently ―. The company's EPS TTM is CHF5.611; its P/E ratio is 7.37; and it has a dividend yield of 4.85%. BB Biotech is scheduled to report earnings on July 26, 2024, and the estimated EPS forecast is CHF―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Mar 22	Mar 21	Jun 17	Mar 17
Income Statement	-
Total Revenue	CHF -222.52M	CHF -298.02M	CHF 223.06M	CHF 113.08M	CHF 376.79M
Ebit	-	-	-	-	-
Ebitda	-	-	-	-	-
Net Income Common Stockholders	CHF -233.06M	CHF -299.86M	CHF 220.95M	CHF 103.39M	CHF 375.00M
Balance Sheet	-
Total Assets	CHF 2.85B	CHF 3.12B	-	CHF 3.36B	CHF 3.53B
Total Debt	CHF 326.00M	CHF 355.00M	CHF 0.00	CHF 0.00	CHF 310.00M
Net Debt	CHF -2.52B	CHF -2.76B	CHF 0.00	CHF -3.33B	CHF -3.22B
Total Liabilities	CHF 334.46M	CHF 359.64M	-	CHF 30.12M	CHF 313.67M
Stockholders Equity	CHF 2.52B	CHF 2.76B	-	CHF 3.33B	CHF 3.22B
Cash Flow	-
Free Cash Flow	CHF 37.34M	CHF 221.08M	CHF -100.02M	CHF 319.69M	CHF 52.41M
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	CHF -37.32M	CHF -223.00M	CHF 96.92M	CHF -302.45M	CHF -56.19M

Currency in CHF

BB Biotech Earnings and Revenue History

Income Statement >

BB Biotech Debt to Assets

Balance Sheet >

BB Biotech Cash Flow

Cash Flow >

BB Biotech Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing